Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
MediLink Therapeutics (Suzhou) Co., Ltd. clinical trials
The registry lists 23 studies whose lead sponsor is MediLink Therapeutics (Suzhou) Co., Ltd.. 18 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 14, 2026.
Keep track of what changes. Save the MediLink Therapeutics (Suzhou) Co., Ltd. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to MediLink Therapeutics (Suzhou) Co., Ltd..
- MediLink Therapeutics (Suzhou) Co., Ltd.23 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 23 of 23.
- A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BCRecruitingNCT06439771Phase 2
- A Study of YL202 in Patients With Advanced Solid TumorsRecruitingNCT07202364Phase 2
- A First-in-Human Study of YL217 in Patients With Advanced Solid TumorsRecruitingNCT06859762Phase 1
- A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid TumorsRecruitingNCT07407933Phase 1/2
- A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based Systemic ChemotherapyNot yet recruitingNCT07803783Phase 3
- A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung CancerRecruitingNCT07739758Phase 3
- Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid TumorsRecruitingNCT06384352Phase 1
- A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line TherapyRecruitingNCT07487896Phase 3
- A Study of YL201 in Patients With Advanced Solid TumorsRecruitingNCT05434234Phase 1/2
- A Study of YL201 and Ivonescimab (AK112) in Advanced Solid TumorsRecruitingNCT07208773Phase 1/2
- Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung CancerRecruitingNCT07416994Phase 3
- YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast CancerRecruitingNCT07461454Phase 3
- A Study of YL242 in Subjects With Advanced Solid TumorsRecruitingNCT07197827Phase 1/2
- A Clinical Study of YL205 in Patients With Advanced Solid TumorsRecruitingNCT06459973Phase 1/2
- A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.RecruitingNCT07258979Phase 1/2
- A Study of YL202 in Selected Patients With Advanced Solid TumorsRecruitingNCT06107686Phase 2
- A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid TumorsRecruitingNCT07169994Phase 1/2
- A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPCRecruitingNCT06241846Phase 2
- A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma (TAISHAN-301)Active, not recruitingNCT06629597Phase 3
- A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer (TAISHAN-302)Active, not recruitingNCT06612151Phase 3
- A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid TumorsActive, not recruitingNCT06394414Phase 1
- A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast CancerActive, not recruitingNCT05653752Phase 1
- A Study YL201 in Patients With Selected Advanced Solid TumorsActive, not recruitingNCT06057922Phase 1/2